Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07362225 · ClinicalTrials.gov registry record
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
A clinical trial of Myelofibrosis and Polycythemia Vera, sponsored by MPN Research Foundation.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 2
- Study locations
NCT07362225 is a study of Myelofibrosis and Polycythemia Vera that is actively recruiting participants, run by MPN Research Foundation. The registered enrollment target is 5,000 participants, above the 114-participant average among 61 other Myelofibrosis trials with a reported enrollment target (4286% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT07362225, a study of Myelofibrosis and Polycythemia Vera, is actively recruiting participants, sponsored by MPN Research Foundation.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), pre-fibrotic primary myelofibrosis (pre-PMF), secondary myelofibrosis, myeloproliferative neoplasm-unclassifiable (MPN-U), MPN in accelerated phase (MPN-AP), and MPN in blast phase (MPN-BP), post-MPN Acute Myeloid Leukemia (AML), and MDS/MPN overlap syndrome as defined above per WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more SCTs and/or BMTs . These conditions are characterized by abnormal blood cell production in the bone marrow and may lead to complications such as blood clots, bleeding, bone marrow fibrosis, and, in some cases, progression to acute leukemia. The central hypothesis of the registry is that collecting and analyzing real-world, longitudinal data-including electronic health records (EHRs), laboratory values, treatments, and patient-reported outcomes (PROs)-from a diverse population of people living with MPNs will help identify patterns and predictors of disease progression, treatment response, quality of life, and long-term outcomes. These insights are intended to guide future research, inform clinical guidelines, and support improvements in patient care. The registry is non-interventional and observational; participants do not receive investigational treatments, and all medical care continues under the supervision of their own physicians. Data collection includes EHRs, PRO surveys, patient-reported symptom and lab tracking, insurance claims, and, in the future, may include linkages with other relevant disease registries and datasets. Potential collaborations under consideration include those with the European LeukemiaNet (ELN) MPN Registry, the Mayo Clinic MPN Database, the Center for Internation
Conditions Studied
Study Locations (2)
Illinois
- MPN Research Foundation - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2035-09-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07362225
The ClinicalTrials.gov registry entry for NCT07362225 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 61 other Myelofibrosis trials with a reported enrollment target (4286% higher). The listed sponsor is MPN Research Foundation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT07362225 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT07362225 about?
NCT07362225 is a clinical study titled "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)". The MPN PROGRESSion Registry is a multi-year, observational research study designed to improve understanding of myeloproliferative neoplasms (MPNs)-a group of rare, chronic blood cancers that include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), pre-fibrotic pri...
What is the current status of trial NCT07362225?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2025-09-26. Estimated completion is 2035-09-08.
What conditions does trial NCT07362225 study?
This clinical trial studies the following conditions: Myelofibrosis, Polycythemia Vera, Myelofibrosis (MF), Polycythemia Vera (PV), ET (Essential Thrombocythemia).
Who is sponsoring clinical trial NCT07362225?
This trial is sponsored by MPN Research Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07362225 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.